← Eichor
Study identifier: NCT05899361 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Condition: Urologic Cancer · Urologic Neoplasms · Bladder Cancer  ·  Sponsor: Dana-Farber Cancer Institute

PhaseNA
Planned participants10
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe imaging will aid in reducing the complexity of both laparoscopic lymphadenectomy and/or organ removal in patients with a confirmed diagnosis of cancer in urologic regions of interest (Bladder, Prostate, Testicular, Kidney, Urethral, and Penis), by resulting in better visualization and more accurate localization of certain areas in the diseased organ or the diseased lymph node, and allowing for improved surgical and patient outcomes, fewer complications and better clinician performance.

This description comes directly from the study's public registry record.

Talk to the study team

Matthew Mossanen, MD  ·  617-525-6348  ·  mmossanen@bwh.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05899361